The reduction in price target by JP Morgan is likely to be viewed negatively by the market, potentially leading to a short-term decline in GoodRx Holdings' stock price. The Neutral rating suggests no significant change in the company's outlook, but the lower price target indicates a reduced valuation by the analyst.